AP reported that Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion.
Valeant said it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson. Read the full story